**SUNDAY, MARCH 21**
Arrival and Registration

**MONDAY, MARCH 22**
Welcome and Keynote Session (Joint)
Helen H. Hobbs, University of Texas Southwestern Medical Center, USA
- PNPLA3's Role in NAFLD
Hashem B. El-Serag, Baylor College of Medicine, USA
- Changing Epidemiological Trends in Non-Alcoholic Fatty Liver Disease versus Viral-Associated Hepatobiliary Cancers
Non-Alcoholic Fatty Liver Disease, Liver Inflammation and Fibrogenesis in the Pathogenesis of Hepatobiliary Cancers (Joint)
Lopa Mishra, George Washington University, USA
- TGF-beta Signaling in Liver Fibrosis and Hepatocellular Carcinoma
Speaker to be Announced
Short Talks Chosen from Abstracts
- Genetics of NAFLD (X5)
  - Elizabeth K. Speliotes, University of Michigan, USA
    Use of GWAS to Identify SNPs Associated with NAFLD
  - Hannele Yki-Järvinen, University of Helsinki, Finland
    Effects of Genetic Risk Factors for NAFLD on Hepatic Lipid Metabolism
  - Noura S. Abul-Husn, Icahn School of Medicine at Mount Sinai, USA
    HSD17B13 and Protection from Liver Disease in Diverse Patient Populations
Short Talks Chosen from Abstracts
- The Role of the Microbiome in Hepatobiliary Cancers (X6)
  - Maria Rescigno, Humanitas University, Italy
    The Gut-Liver Axis in Liver Cancer Risk Conditions
  - Yining Lu, Tsinghua University, China
    China’s Innovative Practice on Precision Immunotherapy of Hepatobiliary Carcinoma: From Outcome Prediction to New Therapeutic Approaches
Speaker to be Announced
Short Talks Chosen from Abstracts
Poster Session 1

**TUESDAY, MARCH 23**
Role of Lipids in NAFLD (X5)
- Mitchell A. Lazar, Perelman School of Medicine, University of Pennsylvania, USA
  Circadian Contributions to NAFLD
- Daniel A. Heller, Memorial Sloan Kettering Cancer Center, USA
  Lipid Dysregulation in Inflammation, NASH, and Cancer
- Catherine Postic, INSERM, Institut Cochin, France
  Altered Insulin Signaling and Glucose Toxicity in NAFLD
- Tobias C. Walther, Harvard School of Public Health, USA
  Lipid Droplet Biology in NAFLD
Short Talks Chosen from Abstracts
- Tumor Microenvironment and Hepatobiliary Cancers (X6)
  - Silvia Affo, Columbia University, USA
    The Role of Cancer-Associated Fibroblasts in the Pathogenesis of Hepatobiliary Cancers
  - Amaia Lujambio, Icahn School of Medicine at Mount Sinai, USA
    Mechanisms of Immune Escape in Hepatocellular Carcinoma
  - Gregory J. Gores, Mayo Clinic, USA
    Targeting the Tumor Microenvironment for Cholangiocarcinoma Therapy
Short Talks Chosen from Abstracts
NAFLD and CVD (X5)
Speaker to be Announced
- Jay D. Horton, University of Texas Southwestern Medical Center, USA
  Molecular Mediators of NAFLD and Hyperlipidemia
- Henry N. Ginsberg, Columbia University College of Physicians and Surgeons, USA
  Loss of Function of TorsinA, an ER Localized AAA ATPase Causes Severe Steatosis with Decreased VLDL Secretion and Abnormal ER Lipid Droplets
Short Talks Chosen from Abstracts
Hepatobiliary Cancer Biomarkers (X6)
- Yujin Hoshida, UT Southwestern Medical Center, USA
  Liver Cancer Risk-Predictive Molecular Biomarkers Specific to Clinico-Epidemiological Contexts
- Irene Oi Lin Ng, University of Hong Kong, Hong Kong
  Molecular Biomarkers in Hepatocellular Carcinoma
- Speaker to be Announced
  • Invited but not yet accepted
  Program current as of June 20, 2020. Program subject to change. Meal formats are based on meeting venue. For the most up-to-date details, visit [https://www.keystonesymposia.org](https://www.keystonesymposia.org).
**Fatty Liver Disease and Multi-System Complications (X5)**

Scientific Organizers: Jay D. Horton, Morris J. Birnbaum and Hannele Yki-Järvinen

Supported by the Directors' Fund

**Hepatobiliary Cancers: Pathobiology and Translational Advances (X6)**

Scientific Organizers: Alphonse E. Sirica, Gregory J. Gores and Lopa Mishra

March 21-24, 2021 • Fairmont Hotel Vancouver • Vancouver, BC, Canada

Supported by the Directors' Fund

Scholarship Deadline: December 9, 2020 / Abstract Deadline: January 5, 2021 / Discounted Registration Deadline: January 20, 2021

---

Augusto Villanueva Rodriguez, Icahn School of Medicine at Mount Sinai, USA

*Liquid Biopsy in Hepatobiliary Cancers*

Short Talks Chosen from Abstracts

---

**WEDNESDAY, MARCH 24**

**Pathways to NASH (X5)**

Speaker to be Announced

Mark A. McNiven, Mayo Clinic, USA

*Lipid Droplet Formation and Lipophagy in Fatty Liver Disease*

Eran Elinav, Weizmann Institute of Science, Israel

*Lipid-Associated Macrophages Control Metabolic Homeostasis*

Speaker to be Announced

Short Talks Chosen from Abstracts

**Genomic and Epigenomic Heterogeneity in Hepatobiliary Cancers (X6)**

Xin Wei Wang, NCI, National Institutes of Health, USA

*Causes and Functional Intricacies of Intertumor and Intra-tumor Heterogeneity in Primary Hepatobiliary Cancers*

Jessica Zucman-Rossi, University Paris Descartes-HEGP, France

*Molecular Subtypes of Hepatocellular Carcinoma are Related to Specific Tumor Phenotypes*

Renumathy Dhanasekaran, Stanford University, USA

*Complexities of Genetic Heterogeneity in Hepatocellular Carcinoma*

Bin Tean Teh, Duke-NUS Medical School, Singapore

*Cholangiocarcinoma in Diverse Populations*

Short Talks Chosen from Abstracts

**Emerging Therapies for NASH-I (X5)**

Morris J. Birnbaum, Pfizer Inc., USA

*DGAT2 Inhibition for NASH*

Speaker to be Announced

Greg Steinberg, McMaster University, Canada

*Cellular Energy Sensors and Metabolism*

Short Talks Chosen from Abstracts

**“Omics” for Precision Medicine of Hepatobiliary Cancers (X6)**

Josep Llovet, Icahn School of Medicine at Mount Sinai, USA

*Integrative “Omics” and Precision Medicine for Hepatocellular Carcinoma*

Jesper Bøje Andersen, University of Copenhagen, Denmark

*Defining Distinct Subtypes of Intrahepatic Cholangiocarcinoma by Molecular Profiling: Diagnostic, Prognostic, and Therapeutic Applications*

---

Robert F. Schwabe, Columbia University, USA

*Discovery of Subgroup-Specific HCC Master Regulators by Systems Biology Approaches*

Short Talks Chosen from Abstracts

**Emerging Therapies for NASH-II (X5)**

Kendra K. Bence, Pfizer Inc., USA

*Inhibition of Fructose Metabolism for the Treatment of NAFLD*

Chuhan Chung, Gilead Sciences, USA

*ACC Inhibitors for NASH*

Lei Ling, NGM Biopharmaceuticals, USA

*Therapeutic FGF19 in Non-Alcoholic Steatohepatitis*

Short Talks Chosen from Abstracts

**Advances in Molecular and Immune Targeting of Hepatobiliary Cancers (X6)**

Bruno Sangro, Clinica Universidad de Navarra, Spain

*Targeted Agent and Immune-Based Therapies for Hepatocellular Carcinoma*

Tim F. Greten, NCI, National Institutes of Health, USA

*Immunotherapies for Hepatobiliary Cancers: Current Status and Future Perspectives*

R. Kate Kelley, University of California, San Francisco, USA

*Developing Clinical Trials of Novel Therapeutic Agents and Treatment Combinations for Intrahepatic Cholangiocarcinoma*

Short Talks Chosen from Abstracts

**Meeting Wrap-Up: Outcomes and Future Directions (Organizers) (X5)**

**Meeting Wrap-Up: Outcomes and Future Directions (Organizers) (X6)**

---

**THURSDAY, MARCH 25**

Departure